FY2030 Earnings Estimate for AMLX Issued By HC Wainwright

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) – Research analysts at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for Amylyx Pharmaceuticals in a report issued on Monday, January 26th. HC Wainwright analyst A. Fein anticipates that the company will post earnings per share of $1.70 for the year. HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Amylyx Pharmaceuticals’ current full-year earnings is ($2.20) per share.

Other equities research analysts have also recently issued research reports about the company. Bank of America boosted their target price on Amylyx Pharmaceuticals from $14.00 to $16.00 and gave the stock a “buy” rating in a research note on Friday, October 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research note on Monday, December 29th. Lifesci Capital upgraded shares of Amylyx Pharmaceuticals to a “strong-buy” rating in a research report on Monday, October 27th. Wall Street Zen cut shares of Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, December 20th. Finally, Robert W. Baird raised their price target on Amylyx Pharmaceuticals from $10.00 to $19.00 and gave the company an “outperform” rating in a report on Thursday, October 16th. Two research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $17.25.

Amylyx Pharmaceuticals Stock Performance

NASDAQ AMLX opened at $15.01 on Tuesday. The firm has a market cap of $1.65 billion, a price-to-earnings ratio of -8.34 and a beta of -0.31. The firm has a 50 day simple moving average of $13.42 and a 200-day simple moving average of $12.00. Amylyx Pharmaceuticals has a one year low of $2.60 and a one year high of $17.49.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last announced its earnings results on Thursday, November 6th. The company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.06.

Insiders Place Their Bets

In related news, CFO James M. Frates sold 3,326 shares of the company’s stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an average price of $11.11, for a total value of $36,951.86. Following the sale, the chief financial officer owned 177,104 shares of the company’s stock, valued at approximately $1,967,625.44. This represents a 1.84% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Camille L. Bedrosian sold 6,580 shares of the business’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $14.35, for a total value of $94,423.00. Following the completion of the transaction, the insider directly owned 175,756 shares of the company’s stock, valued at approximately $2,522,098.60. This trade represents a 3.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 157,783 shares of company stock valued at $2,122,808. Corporate insiders own 12.30% of the company’s stock.

Institutional Investors Weigh In On Amylyx Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Millennium Management LLC lifted its stake in shares of Amylyx Pharmaceuticals by 418.6% during the first quarter. Millennium Management LLC now owns 3,081,853 shares of the company’s stock valued at $10,910,000 after buying an additional 2,487,617 shares during the period. Goldman Sachs Group Inc. lifted its stake in shares of Amylyx Pharmaceuticals by 7.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,002,961 shares of the company’s stock worth $7,090,000 after purchasing an additional 143,065 shares during the period. Y Intercept Hong Kong Ltd acquired a new stake in shares of Amylyx Pharmaceuticals during the second quarter worth $1,541,000. Los Angeles Capital Management LLC purchased a new stake in shares of Amylyx Pharmaceuticals in the second quarter valued at $149,000. Finally, Acadian Asset Management LLC grew its position in shares of Amylyx Pharmaceuticals by 135.1% in the second quarter. Acadian Asset Management LLC now owns 569,083 shares of the company’s stock valued at $3,645,000 after purchasing an additional 326,976 shares during the period. 95.84% of the stock is currently owned by hedge funds and other institutional investors.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.